Eli Lilly has announced plans to expand its U.S. pharmaceutical manufacturing with four new sites, increasing its total domestic capital expansion commitments to over $50 billion since 2020.
Three of the four facilities will focus on active pharmaceutical ingredient (API) production, reinforcing Lilly’s supply chain by reshoring essential small-molecule chemical synthesis. The fourth site will enhance the company’s global parenteral manufacturing network, supporting future injectable treatments.
The construction phase will create approximately 10,000 jobs, while the new facilities will employ 3,000 skilled professionals, including operations staff, scientists, lab technicians, and engineers. These investments will drive economic growth in their respective communities through increased local spending, infrastructure development, tax revenue, and workforce training opportunities.
Edgardo Hernandez, Lilly’s President of Manufacturing Operations and Executive Vice President, stated:
“To deliver on our big bets on next-generation modalities—small molecules, biologics, and nucleic acid therapies—Lilly is investing in state-of-the-art manufacturing infrastructure to ensure the safe and reliable medicines of tomorrow. We are not just building facilities; we are fostering a future where American innovation leads the world in pharmaceutical manufacturing, powered by a highly skilled workforce.”
Between 2020 and 2024, Lilly committed $23 billion to domestic capital expansion, reflected in this $50 billion announcement. Previous investments include sites in Research Triangle Park and Concord (North Carolina), upgrades to Indianapolis facilities, the LEAP Innovation District and Lilly Medicine Foundry (Lebanon, Indiana), and the acquisition and expansion of a manufacturing site in Kenosha County, Wisconsin.
In August 2024, Lilly also opened the Seaport Innovation Center, a research and development hub in Boston’s Seaport district.